CA3025366A1 - Methods and compositions for modulating lymphatic vessels in the central nervous system - Google Patents

Methods and compositions for modulating lymphatic vessels in the central nervous system Download PDF

Info

Publication number
CA3025366A1
CA3025366A1 CA3025366A CA3025366A CA3025366A1 CA 3025366 A1 CA3025366 A1 CA 3025366A1 CA 3025366 A CA3025366 A CA 3025366A CA 3025366 A CA3025366 A CA 3025366A CA 3025366 A1 CA3025366 A1 CA 3025366A1
Authority
CA
Canada
Prior art keywords
subject
vegfr3
meningeal
cells
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3025366A
Other languages
English (en)
French (fr)
Inventor
Jonathan Kipnis
Antoine LOUVEAU
Sandro DA MESQUITA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Original Assignee
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia Patent Foundation filed Critical University of Virginia Patent Foundation
Publication of CA3025366A1 publication Critical patent/CA3025366A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3025366A 2016-06-01 2017-05-31 Methods and compositions for modulating lymphatic vessels in the central nervous system Pending CA3025366A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344164P 2016-06-01 2016-06-01
US62/344,164 2016-06-01
PCT/US2017/035285 WO2017210343A1 (en) 2016-06-01 2017-05-31 Methods and compositions for modulating lymphatic vessels in the central nervous system

Publications (1)

Publication Number Publication Date
CA3025366A1 true CA3025366A1 (en) 2017-12-07

Family

ID=60477853

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3025366A Pending CA3025366A1 (en) 2016-06-01 2017-05-31 Methods and compositions for modulating lymphatic vessels in the central nervous system

Country Status (6)

Country Link
US (1) US11944665B2 (https=)
EP (1) EP3463575B1 (https=)
JP (2) JP2019522044A (https=)
AU (1) AU2017273629B2 (https=)
CA (1) CA3025366A1 (https=)
WO (1) WO2017210343A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114949182A (zh) * 2022-04-07 2022-08-30 上海大学 一种淋巴管生成诱导剂的用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210343A1 (en) 2016-06-01 2017-12-07 The University Of Virginia Patent Foundation Methods and compositions for modulating lymphatic vessels in the central nervous system
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US12352767B2 (en) 2018-07-16 2025-07-08 University Of Virginia Patent Foundation Method of treating cognitive decline associated with neurological diseases based on a decrease in FLT4 expression or activity
CN113226283A (zh) * 2018-10-04 2021-08-06 罗切斯特大学 通过操纵血浆重量摩尔渗透压浓度改善淋巴递送
WO2020102627A1 (en) 2018-11-16 2020-05-22 Yale University Manipulation of meningeal lymphatic vasculature for brain and cns tumor therapy
WO2021071830A1 (en) 2019-10-07 2021-04-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
US20240207362A1 (en) * 2022-10-25 2024-06-27 Institute For Basic Science (Ibs) Extracranial Methods For Facilitating Cerebrospinal Fluid Drainage
JP2026510233A (ja) * 2023-02-16 2026-04-02 ユニバーシティー オブ ロチェスター グリンパ－リンパ流出の改善

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132098B1 (en) * 1999-09-21 2010-05-26 AnGes MG, Inc. Gene therapy for cerebrovascular disorders
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20080057028A1 (en) 2002-10-02 2008-03-06 Institute Nationale De La Sante Et De La Recherche Medicale (Inserm) Vegf-C or Vegf-D Materials and Methods for Stimulation of Neural Stem cells
US9415090B2 (en) * 2011-06-01 2016-08-16 Universität Heidelberg VEGF-D/VEGFR2/3-mediated regulation of dendrites
US8852936B2 (en) * 2012-09-21 2014-10-07 Laurantis Pharma Oy Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
WO2017190074A1 (en) 2016-04-28 2017-11-02 The University Of Chicago Lymphangiogenesis for therapeutic immunomodulation
WO2017210343A1 (en) 2016-06-01 2017-12-07 The University Of Virginia Patent Foundation Methods and compositions for modulating lymphatic vessels in the central nervous system
WO2020102627A1 (en) 2018-11-16 2020-05-22 Yale University Manipulation of meningeal lymphatic vasculature for brain and cns tumor therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114949182A (zh) * 2022-04-07 2022-08-30 上海大学 一种淋巴管生成诱导剂的用途

Also Published As

Publication number Publication date
US11944665B2 (en) 2024-04-02
EP3463575A1 (en) 2019-04-10
EP3463575B1 (en) 2025-03-26
US20190269758A1 (en) 2019-09-05
AU2017273629B2 (en) 2023-06-08
AU2017273629A1 (en) 2018-12-13
JP2022031368A (ja) 2022-02-18
JP2019522044A (ja) 2019-08-08
WO2017210343A1 (en) 2017-12-07
EP3463575A4 (en) 2020-01-29

Similar Documents

Publication Publication Date Title
AU2017273629B2 (en) Methods and compositions for modulating lymphatic vessels in the central nervous system
Matsushita et al. Diffuse and persistent blood–spinal cord barrier disruption after contusive spinal cord injury rapidly recovers following intravenous infusion of bone marrow mesenchymal stem cells
US20200345812A1 (en) Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
JP6920324B2 (ja) 神経細胞の損失予防及び再生の効能を有するペプチド及びこれを含む組成物
ES2546093T3 (es) VEGF para utilizar en el tratamiento de trastornos del sistema nervioso central
Osterstock et al. Sustained alterations of hypothalamic tanycytes during posttraumatic hypopituitarism in male mice
KR20150018555A (ko) 뇌졸중 후 신경발생을 촉진시키는 세마포린-４d 결합 분자의 용도
AU2020363372A1 (en) Modulating lymphatic vessels in neurological disease
ES2825101T3 (es) Composiciones y métodos para el tratamiento de trastornos neuropsiquiátricos usando un agonista del receptor de la endotelina B
AU2011314074B2 (en) ND2 peptides and methods of treating neurological disease
Feng et al. Meningeal lymphatics as a therapeutic target for neurodegenerative disorders
CA3169224C (en) METHODS, COMPOUNDS AND COMPOSITIONS INTENDED TO MODULATE THE INTEGRITY OF THE BLOOD-BRAIN BARRIER AND REMYELINATION
Xu et al. Increased expression of placental growth factor in patients with temporal lobe epilepsy and a rat model
Gänger Uptake, distribution and elimination of intranasally-delivered immunoglobulin G in vivo and suggestions for intranasal drug formulations tailored for the olfactory mucosa
Lengning Role of neuroblast-derived signals in post-stroke neurovascular remodeling
Wang et al. The liver and muscle secreted Hfe2-protein maintains blood brain barrier integrity
Mandler Characterisation of neuropathologic alterations following active immunotherapy against Aβ
WO2024089620A1 (en) Extracranial methods for facilitating cerebrospinal fluid drainage
류정화 A study on the attenuating effects of neuregulin-1 on cognitive function impairments and its action mechanisms in an Alzheimers disease animal model
Hawk Retrograde influences of peripheral nerve injury on uninjured neurons
Sharma Efficacy of a novel neuronal death inhibitor in Alzheimer’s disease models
WO2017202814A1 (en) Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220526

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240909

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251117

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260119